{
    "id": 80202,
    "name": "adenoid cystic carcinoma",
    "source": "DOID",
    "definition": "An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. [url:http\\://codes.iarc.fr/code/2592, url:https\\://en.wikipedia.org/wiki/Adenoid_cystic_carcinoma, url:https\\://meshb.nlm.nih.gov/record/ui?ui=D003528]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0080202",
    "evidence": [
        {
            "id": 9897,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with adenoid cystic carcinoma demonstrated a metabolic response when treated with LY3039478 (European Journal of Cancer, Volume 69, S15).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8303,
                    "pubMedId": null,
                    "title": "First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer",
                    "url": "http://www.sciencedirect.com/science/article/pii/S0959804916326326?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11625,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Dovitinib (TKI258) treatment was tolerated and demonstrated limited clinical activity in patients with adenoid cystic carcinoma, resulting in partial response in 5.9% (2/34) of patients, suppression of overall tumor growth rate, and a median progression-free survival of 8.2 months (PMID: 28377480).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9673,
                    "pubMedId": 28377480,
                    "title": "A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28377480"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21017,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth in a patient-derived xenograft model of adenoid cystic carcinoma harboring NOTCH1 I1680N (PMID: 27870570).",
            "molecularProfile": {
                "id": 778,
                "profileName": "NOTCH1 I1680N"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21018,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brontictuzumab (OMP-52M51) did not inhibit tumor growth in a patient-derived xenograft model of adenoid cystic carcinoma harboring NOTCH1 S1004L (PMID: 27870570).",
            "molecularProfile": {
                "id": 35494,
                "profileName": "NOTCH1 S1004L"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21019,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs achieved a partial response after 2 doses of Brontictuzumab (OMP-52M51), however, his disease progressed shortly after treatment discontinuation (PMID: 27870570).",
            "molecularProfile": {
                "id": 35495,
                "profileName": "NOTCH1 L1600Q NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21020,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, FBXW7 W606* and NOTCH1 V1721G were identified at disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs who was treated with Brontictuzumab (OMP-52M51) (PMID: 27870570).",
            "molecularProfile": {
                "id": 35498,
                "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21021,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Sutent (sunitinib) treatment resulted in rapid disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs, and acquired FBXW7 W606* and NOTCH1 V1721G (PMID: 27870570).",
            "molecularProfile": {
                "id": 35498,
                "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02098538",
            "title": "Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02780310",
            "title": "Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03087019",
            "title": "Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03172624",
            "title": "Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03691207",
            "title": "A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2545,
                    "therapyName": "BMS-906024",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03990571",
            "title": "Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3145,
                    "therapyName": "Avelumab + Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04209660",
            "title": "Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}